Sector News

AZ announces $4-billion deal for majority stake in Acerta

December 17, 2015
Life sciences

AstraZeneca how has confirmed that it intends to take a majority stage in privately held US/Dutch clinical stage biopharma Acerta Pharma in a deal valued at $4 billion.

The drugs giant said it will pay Acerta $2.5 billion upfront, plus an unconditional $1.5 billion either on receipt of the first regulatory approval for cancer drug acalabrutinib in the US, or the end of 2018, depending on which comes first.

The agreement also provides Acerta’s shareholders the opportunity to sell, and AZ to buy, the remaining 45% of the firm’s shares. These options can be exercised at various points in time, conditional on the first approval of acalabrutinib in both the US and Europe and when the extent of the commercial opportunity has been fully established, at a price of around $3 billion net of certain costs and payments incurred by AZ.

Acalabrutinib is being tested in a variety of leukaemia’s, lymphomas and other cancers, and alongside Merck & Co’s immunotherapy Keytruda (pembrolizumab). The drug is a BTK inhibitor with a mode of action similar to AbbVie/Johnson & Johnson’s blood cancer drug Imbruvica (ibrutinib), which is widely expected to rake in peak sales in excess of $5 billion.

Early clinical data looks promising; results from a Phase I/II study recently published in the New England Journal of Medicine showed a 95 percent response rate in patients with relapsed chronic lymphocytic leukaemia, the most prevalent form of adult leukaemia.

“Acalabrutinib provides us with a small molecule presence in blood cancers to complement our existing immunotherapy approach, in collaboration with Celgene in haematological malignancies,” said AZ’ chief executive Pascal Soriot. “Furthermore, we look forward to working closely with the Acerta team and benefiting from the considerable clinical expertise they bring in this complex area of medicine”.

The move falls in line with AZ’ strategy of focusing acquisitions to boost its long-term growth prospects. Just last month, the company announced plans to buy US biotech ZS Pharma for $2.7 billion, gaining access to its flagship cardiovascular compound, a potential best-in-class treatment for hyperkalaemia – a condition characterised by elevated levels of potassium in the blood linked with increased mortality in chronic kidney disease and coronary heart failure.

The transaction with Acerta is expected to complete by the end of the first quarter of 2016, subject to customary closing conditions, and be moderately dilutive to AZ’ core earnings in the near term.

By Selina McKee

Source: Pharma Times

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach